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Background: Ulinastatin is a glycoprotein derived from human urine and a serine protease inhibitor found in 
human urine and blood. Ulinastatin increases both liver blood flow and urine output. Rocuronium is eliminated 
mainly through the liver and partly through the kidney, hepatic elimination of rocuronium might be enhanced by 
ulinastatin. We examined the effect of ulinastatin on the neuromuscular block caused by rocuronium. 
Methods: Forty four adult patients were randomly divided into two groups of 22 patients each, i.e. the study group 
and the control group. In the study group, a bolus dose of ulinastatin 5,000 U/kg was administered 2 min before the 
injection of rocuronium 0.6 mg/kg. In the control group, normal saline was administered instead of ulinastatin. For 
the monitoring of both onset and recovery from neuromuscular blockade, train­of­four (TOF) and post­tetanic count 
were used with TOF­Watch Sx. All patients underwent general anesthesia with total intravenous anesthesia (TIVA) of 
remifentanil and propofol, using the effect site target infusion system.
Results: In the study group, the onset of neuromuscular block was significantly slower than in the control group (P < 
0.05). The recovery time from the rocuronium injection to the return of PTC was also significantly shorter in the study 
group than in the control group (P < 0.05). Similarly, times to the return of T1, T2, T3, and T4 (i.e. the first, second, 
third, and fourth response of TOF) were significantly shorter in the study group than in the control group (P < 0.05). 
Conclusions: Ulinastatin significantly delays the onset of neuromuscular block and accelerates the recovery from the 
block caused by rocuronium. (Korean J Anesthesiol 2012; 62: 240­244)
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Introduction
Rocuronium, the 2­morpholino, 3­desacetyl, 16­N­allylpyr­
roli  dino derivative of vecuronium, is an aminosteroid, non­
depolarizing neuromuscular blocking agent [1]. It is widely 
used during anesthesia for its short onset time and intermediate 
duration of action, similar to that of vecuronium [1­3]. The 
pharmacokinetics of rocuronium also resembles those of 
vecuronium. Thus, rocuronium has relatively rapid onset of 
neuromuscular block and an intermediate duration of action. 
In constrast to vecuronium, however, rocuronium has no 
metabolite [3]. Although hepatic uptake and biliary excretion 
have been suggested to be the main mechanisms of rocuronium 
metabolism, a previous study in humans has shown that a 33% 
of a rocuronium dose of 1 mg/kg was recovered from urine 
within 24 h [4]. 
Urinary trypsin inhibitor (ulinastatin, UTI, Ulistin
Ⓡ, Han Lim 
Pharmaceutical, Seoul, Korea) is an intrinstic serine­protease 
inhibitor, which is extracted and purified from human urine 
[5,6]. Because ulinastatin increases both liver blood flow [7] and 
urine output [8], and rocuronium is eliminated mainly through 
the liver and partly through the kidney [4], hepatic elimination 
of rocuronium might be enhanced by ulinastatin. A previous 
study on protease inhibitor homologues showed that ulinastatin 
releases acetylcholine at the neuromuscular junction, and this 
may cause resistance to rocuronium [9]. Saitoh et al. [10] reported 
that, in anaesthetized healthy patients, the administration of 
ulinastatin delayed the onset of neuromuscular block and 
accelerated the recovery from vecuronium induced neruo­
muscular block. 
In this study, we hypothesized that ulinastatin will also 
accelerate the recovery of rocuronium­induced neuromuscular 
block. To the best of our knowledge, the neuro  muscular effect of 
rocuronium after the administration of ulinastatin has not been 
investigated previously. 
Therefore, the aim of the present study was to investigate 
the onset of neuromuscular block and recovery of post­tetanic 
count (PTC) and train­of­four (TOF) responses, after admini­
stration of ulinastatin, in anesthetized patients receiving rocuro­
nium.
Materials and Methods
After approval and, This study was approved by the Insti­
tutional Review Board and informed consent was obtained 
from all participants. In total, 44 patients with American Society 
of Anesthesiologists physical status I or II and undergoing 
elective surgery with a general anesthesia technique were 
studied. Exclusion criteria included body weight 30% greater 
than the ideal values, chronic anti  biotic therapy, acute and 
chronic renal or hepatic disease, neuromuscular disorders, 
and previous history of an unusual reaction to neuromuscular 
blocking drugs. The patients were randomly divided into two 
groups of 22 patients each, i.e. the ulinastatin group and the 
control group. Glycopyrrolate 0.2 mg/kg IM was given 30 min 
before the induction of anesthesia, as premedication. The skin 
overlying the ulnar nerve at each wrist was lightly abraded with 
the plastic backing of an ECG electrode and then cleansed 
with isopropyl alcohol. Two electrodes were placed over the 
prepared skin just lateral to the flexor carpi ulnaris tendon. 
A force displacement transducer was attached to the thumb 
of the investigated arm. All patients were fasted for at least 6 
hours before surgery. Anesthesia was performed by the same 
experienced anesthesiologist, assisted by an appropriately 
trained anesthesia nurse. Standard intraoperative monitoring 
included electrocardiograph, non­invasive measurement of 
blood pressure, pulse oximetry, capnography and body tem­
perature (Datex­Ohmeda, Helsinki, Finland). The non­invasive 
blood pressure cuff was placed on the opposite side of the 
arm in which drug was given intravenously, to minimize the 
influence of BP cuff inflation during initial drug distribution. 
After placement of the non­invasive monitors and during 
pre­oxygenation, the TOF­Watch SX (Organon Ireland Limited, 
Dublin, Ireland) peripheral nerve stimulator was calibrated 
by pressing the CAL button for one second. If the initial cali­
bration procedure resulted in maximal stimulating current of 
60 mA, the device was recalibrated, with a maximum of three 
total calibrations, in an effort to reach a lower stimulating 
current. In the ulinastatin group, bolus dose of ulinastatin 
5,000 U/kg was administered intravenously before induction of 
anesthesia. In the control group, 0.1 ml/kg of normal saline was 
given instead of ulinastatin. Immediately after the injection of 
either ulinastatin or normal saline, target of propofol (Fresofol 
2%, Fresenius, Germany) was started at 4 μg/ml and that of 
remifentanil was initially started at 2 ng/ml, for adequate 
induction by an infusion pump (Fresenius Infusomat CP
Ⓡ; 
Bad Homburg, Germany). After the loss of eyelash reflex was 
confirmed, the ulnar nerve was trans­cutaneously stimulated 
supramaximally at the wrist, with square pulses of 0.2 
milliseconds duration, delivered in a TOF sequence at 2 Hz 
and repeated every 12 seconds. The PTC with the TOF­Watch 
peripheral nerve stimulator was obtained by pressing the PTC 
button and recording the result displayed on the monitor. The 
post­tetanic count was repeated at 3 minute intervals, until 
the TOF­Watch stimulator detected the presence of at least 
one twitch prior to PTC. Thereafter, TOF measurements were 
repeated at 12 seconds interval. Before tracheal intubation, 
rocuronium 0.6 mg/kg was administered intravenously. The 
time interval between the administration of either ulinastatin 
or normal saline and that of rocuronium was 2 min. After the 242 www.ekja.org
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rocuronium injection, the disappearance of the TOF response 
was regarded as the onset of neuromuscular block. The time to 
the onset of neuromuscular block was compared between the 
ulinastatin and the control groups. In addition, in both groups, 
time courses of recovery of PTC were compared. The times from 
the injection of rocuronium to the return of T1, T2, T3, and T4 
(i.e. the first, second, third, and fourth response in TOF) were 
compared between the two groups. 
All patients received total intravenous anesthesia (TIVA) of 
remifentanil and propofol using the effect site target infusion 
system. In each group, patients received a mixture of air and 
30% oxygen. 
The initial target of propofol was set at 4 μg/ml; after 
induction, the target was maintained at 4 μg/ml until the end 
of surgery. The target of remifentanil was initially set at 2 ng/
ml and was later adjusted between 2 and 4 ng/ml, according 
to clinical needs. Either the decrease in systolic blood pressure 
below 85 mmHg or the decrease in mean blood pressure below 
55 mmHg was treated by decreasing the target of remifentanil to 
a minimum level of 2 ng/ml. In addition, the patients received 
rapid infusion of Ringer’s acetate solution and/or 5-10 mg of 
intravenous ephedrine, when considered necessary. The fresh 
gas flow was kept at 6 L/min until tracheal intubation, using 
100% oxygen. During maintenance of anesthesia, the gas flow 
was set at 4 L/min, using the above mentioned gas mixture, 
i.e. air plus 30% oxygen. Ventilation was controlled sufficiently 
to maintain normocarbia. The concentrations of anesthetics 
and PET CO2 were measured, using a multiple gas monitor 
(Capnomac Ultima; Datex Inc., Helsinki, Finland). 
All results were expressed as either number of patients 
or mean ± SD. Patient data were compared between the 
two groups, using the analysis of variance (ANOVA) and the 
unpaired t­test. The time to the onset of neuromuscular block 
and the times to the return of PTC were compared between the 
study and control groups, using the unpaired t­test. Similarly, 
times for the return of T1, T2, T3, or T4 responses were compared 
between the study group and control groups, using the unpaired 
t­test. A P value < 0.05 was considered as statistically significant. 
Statistical analyses were performed with the statistical package R 
2.11.1 (R Foundation for Statistical Computing, Vienna, Austria).
Results
There were no differences between the two groups in sex, 
age, body height, and body weight, as presented in Table 1. 
The time to the onset of neuromuscular block was signifi­
cantly longer in the study group than in the control group (268 ± 
62 vs. 151 ± 43s, P < 0.05) (Table 2). 
The time from the rocuronium injection to the return of the 
first PTC response was significantly shorter in the study group 
than in the control group (920 ± 131 vs 730 ± 183s, P < 0.05) 
(Table 2). Also, the times to the return of the T1, T2, T3, and T4 
responses were significantly shorter in the study group than in 
the control group (1,346 ± 257 vs 939 ± 171s, 1,581 ± 255 vs 1,153 
± 198s, 1,765 ± 234 vs 1,331 ± 223s, and 1,925 ± 183 vs 1,433 ± 
227s, respectively, P < 0.05) (Table 2). 
After the administration of either ulinastatin or normal 
saline, no patient showed severe hypertension (i.e. systolic 
arterial pressure > 200 mmHg) or hypotension (i.e. systolic 
arterial pressure < 80 mmHg), severe tachycardia (heart rate 
> 120 bpm), bradycardia (heart rate < 50 bpm), or arrhythmia. 
Discussion
We investigated the neuromuscular block characteristics of 
rocuronium affected by bolus administration of ulinastatin. We 
hypothesized that bolus administration of ulinastatin would 
delay the onset of the rocuronium­induced neuromu  scular block 
and would accelerate the recovery from the neuro          muscular 
Table 1. The Patients’ Characteristics
Control group Ulinastatin group
Number
Sex (M/F)
Age (yr)
Height (cm)
Weight (kg)
22
11/11
41.7 ± 10.2
161.8 ± 7.2
60.0 ± 8.8
22
11/11
43.4 ± 10.3
158.2 ± 23.1
64.3 ± 24.3
Values are given as number or mean ± SD. 
Table 2. Neuromuscular Functional Data 
Control group Study group P value
Time to NM block 
Time to first PTC response
Time to reappearance of T1
Time to reappearance of T2
Time to reappearance of T3
Time to reappearance of T4
151.2 ± 43.6
920.7 ± 131.1
1,346.4 ± 257.5
1,581.1 ± 255.6
1,765.3 ± 234.7
1,925.4 ± 183.4
268.2 ± 62.5
730.6 ± 183.9
939.5 ± 171.3
1,153.3 ± 198.7
1,331.9 ± 223.9
1,433.9 ± 227.6
0.0000005
0.0002
0.0000002
0.000002
0.00000002
0.000002
Values are given as mean ± SD (in seconds). Time to NM block: the time interval between the rocuronium injection and the disappearance of 
the train-of-four response, T1, T2, T3, and T4: the first, second, third, and fourth response in the train-of-four, PTC: Post-tetanic count. 243 www.ekja.org
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block. The times to the return of PTC, T1, T2, T3 and T4 responses 
were shortened because the protease inhi  bitor homolgues 
increase the release of acetylcholine (Ach), in response to 
motor nerve stimulation [10]. It has been demonstrated that 
ulinastatin increases both the liver blood flow [7] and the urine 
output [8]. Rocuronium is eliminated mainly through the 
liver and partly through the kidney [4]; therefore, the hepatic 
elimination of rocuronium might be enhanced by ulinastatin, 
which accelerates the recovery from neuromuscular block. We 
consider that the onset of neuromuscular blockade was delayed 
and the recovery from neuromuscular block was accelerated 
after the administration of ulinastatin.
Ulinastatin, a urinary trypsin inhibitor, is a glycoprotein 
derived from human urine, and is a serine protease inhibitor 
found in human urine and blood [11]. Ulinastatin is secreted 
when inter­α­trypsin inhibitors are degraded by the neutrophilic 
enzyme elastase [11]. It also has been known as mingin, human 
inhibitor 30, miraclid, and bikunin [12]. Ulinastatin is indicated 
in acute inflammatory disorders, including acute pancreatitis, 
systemic inflammatory reaction syndrome (SIRS), circulatory 
insufficiency, disseminated intravascular coagulation (DIC) 
and multiple organ failure [13]. The urinary trypsin inhibitor 
exists naturally in the human body and is secreted in increased 
quantities during stressful conditions, such as inflammation, 
cancer, infection, and tissue damage [14]. It is composed of 143 
amino acid residues and two Kunitz­type protease inhibitor 
domains [15]. Both Kunitz domains inhibit serine proteases, 
especially elastase. The levels of several proteases, such as 
elastase, cathepsin G, and collagenase, increase during both 
infection and inflammation; therefore, protease inhibitors have 
anti­inflammatory activity [15].
To date, knowledge of the routes of elimination of rocuro­
nium has been limited to laboratory animal data and to urinary 
excretion data in man. In animals, 9-25% of radiolabelled 
rocuronium was found in urine and 65-75% in feces [3]. In the 
isolated perfused rat, rocuronium was rapidly taken up, with 
a high extraction ratio, and was rapidly excreted into the bile 
[16]. In cats, 54% of the intravenous dose was found in the bile 
and 21% in liver homogenate [17]. In addition, when the liver 
was excluded from the circulation (via a portal vein­to­inferior 
vena cava shunt), the clinical duration of action of rocuronium 
increased almost threefold [17]. These findings suggest that both 
the pharmacokinetics and the time course of neuromuscular 
effect of rocuronium may be altered by liver disease [18]. 
Since ulinastatin increases the blood flow in the liver [7], the 
hepatic elimination of rocuronium would be increased after 
administration of ulinastatin. 
A previous study in humans has shown that 33% of the 
rocuronium dose of 1 mg/kg was recovered from urine within 
the first 24 hours [4]. Another study showed that about 10% of 
the IV dose of rocuronium was excreted in urine [17,19]. Kocabas 
et al. [20] reported that the clearance of rocuronium was reduced 
by 39% in patients suffering from renal failure compared with 
controls, with 84% increase in the mean residence time, whereas 
the volume of distribution was unaffected by renal failure. 
Therefore, the duration of action of rocuronium can be expected 
to be prolonged, as it undergoes organ­dependent elimination 
[20]. Proost et al. [3] demonstrated that rocuronium is taken up 
by the liver and excreted into the bile in very high concentration 
[3]. The proportion of rocuronium excreted into urine within 
7 days was 26%. Since ulinastatin increases the urine volume 
[8], rocuronium would be rapidly eliminated in the kidney after 
ulinastatin injection. 
In this study, the time interval from the administration of 
ulinastatin to that of rocuronium was 2 min. Sugiki et al. [21] 
reported that the distribution half­life of the protease inhibitor 
was 3.9 min. However, ulinastatin given only 2 mininutes 
before the rocuronium injection significantly delayed the onset 
of the neuromuscular block. There were no previous studies 
investigating the onset of the ulinastatin­induced effect on 
neuromuscular transmission. However, Saitoh et al. [10] reported 
that, after bolus administration of ulinastatin, the ulinastatin­
induced effect on the skeletal muscles may become apparent 
within 2 minutes.
Previous studies done by Saitoh et al. on the effect of ulinastatin 
on vecuronium included isoflurane as the main anesthetic agent; 
isoflurane is known to potentiate non­depolarizing neuro­
muscular blockade [10]. We wanted to exclude any factors that 
could have had any effect on the potency of neuromuscular 
blockade of rocuronium. Therefore, in our study, patients 
received total intravenous anesthesia (TIVA), using target con­
trolled infusion of propofol and remifentanil. The bispectral 
index (BIS) was not monitored in our study. The initial target 
of propofol was set at 4 μg/ml by an infusion pump and the 
target of remifentanil was initially set at 2 ng/ml, and later 
adjusted between 2 and 4 ng/ml, according to clinical needs. Kil 
et al. [22] proved that BIS shows a significant correlation with 
propofol and the effect site concentration of 43.5 μg/kg propofol 
was reached at a BIS of 41.1 ± 2.5. Another study showed that, 
during TIVA, the effect site concentration for blunting the 
hemodynamic response to endotracheal intubation was 3.5 ng/
mL, using the dose of 4.0 μg/ml propofol with remifentanil [23]. 
It has been shown that the onset time of the neuromuscular 
block is partially determined by the cardiac output [24,25]. No 
previous studies examined the ulinastatin­induced changes 
in either cardiac output or blood pressure. However, Ohnishi 
et al. [24] showed that ulinastatin did not significantly alter the 
heart rate after hemorrhagic shock. In this study, there was 
no significant change in blood pressure and heart rate after 
administration of ulinastatin, which may affect the onset time of 244 www.ekja.org
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neuromuscular block. 
In conclusion, in this study, we demonstrated that, in 
anesthetized patients, ulinastatin delays the onset of the rocu­
ronium­induced neuromuscular block and accelerates the 
recovery from the neuromuscular block. This is probably 
because ulinastatin increases the release of acetylcholine (Ach), 
the blood flow in the liver, and the urine volume. 
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